RecruitingNCT05943522

Asciminib RMP Study

A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea

Sponsor

Novartis Pharmaceuticals

Enrollment

600 participants

Start Date

Jul 19, 2023

Study Type

OBSERVATIONAL

Conditions

Chronic Myeloid Leukemia

Summary

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study following people with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (CML) who are being treated with asciminib (brand name Scemblix). The study is collecting real-world data on how this medication works in everyday clinical practice. **You may be eligible if...** - You are an adult diagnosed with Ph+ chronic-phase CML - You are currently receiving or about to start asciminib (Scemblix) as part of your regular care - You are willing to provide written consent **You may NOT be eligible if...** - You have a medical reason (contraindication) that prevents you from taking Scemblix - You are participating in or planning to participate in another clinical drug trial at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAsciminib

There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

Locations(17)

Novartis Investigative Site

Wŏnju, Gangwon-do, South Korea

Novartis Investigative Site

Anyang-si, Gyeonggi-do, South Korea

Novartis Investigative Site

Bucheon-si, Gyeonggi-do, South Korea

Novartis Investigative Site

Uijeongbu-si, Gyeonggi-do, South Korea

Novartis Investigative Site

Gyeonggi-do, Korea, South Korea

Novartis Investigative Site

Incheon, Korea, South Korea

Novartis Investigative Site

Seoul, Korea, South Korea

Novartis Investigative Site

Seoul, Seoul, South Korea

Novartis Investigative Site

Seoul, Seoul, South Korea

Novartis Investigative Site

Seoul, Yangcheon gu, South Korea

Novartis Investigative Site

Suwon, Yeongtong Gu, South Korea

Novartis Investigative Site

Jeollanam, South Korea

Novartis Investigative Site

Pusan, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Taegu, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05943522

Related Trials

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT068177201 location

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069745 locations

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT0530437745 locations

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

NCT035338162 locations

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

NCT062298601 location